Dianthus Therapeutics to Present DNTH103 Posters at EAN Congress

June 28, 2024 -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology firm, announced the presentation of two posters about DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) from June 29 to July 2, 2024, in Helsinki.

DNTH103 is an experimental classical pathway inhibitor, specifically targeting the active form of C1s. It is under investigation as a streamlined and effective treatment for generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy.

The presentations at EAN will showcase preclinical and in vitro data demonstrating DNTH103's distinct profile in models of generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Additionally, they will compare the affinity and pharmacodynamic potency of DNTH103 with Riliprubart.

The Dianthus presentations at EAN are scheduled as follows:
- June 29, 2024, at 14:10 EEST: "DNTH103, a Potentially Safer and More Convenient Novel Therapy for Generalized Myasthenia Gravis" (Session: Muscle and Neuromuscular Junction Disorder 1; Presentation Number: EPR-118)
- June 30, 2024, at 14:25 EEST: "DNTH103: Preventing Nerve Damage in a CIDP Model via Sustained Complement Inhibition" (Session: Muscle and Neuromuscular Junction Disorder 2; Presentation Number: EPR-243)

The posters will be accessible in the Scientific Publications section of the Dianthus website following their presentation.

Current therapies for generalized Myasthenia Gravis (gMG) are limited to C5 inhibitors or FcRn inhibitors, which can be cumbersome for patients and caregivers. C5 complement inhibitors carry a higher risk of serious bacterial infections. Similarly, treatment options for CIDP are typically restricted to intravenous or subcutaneous infusions of immunoglobulins. Marino Garcia, Chief Executive Officer of Dianthus Therapeutics, stated, "We aim to show that DNTH103 can become a best-in-class classical complement pathway inhibitor with infrequent self-administration, providing consistent symptom control for neuromuscular conditions without inhibiting alternative and lectin pathways crucial for infection defense."

DNTH103 is a potent monoclonal antibody designed to selectively inhibit the classical pathway by targeting only the active form of the C1s protein, a validated complement target. Enhanced with YTE half-life extension technology, DNTH103 allows for convenient subcutaneous self-administration as infrequently as once every two weeks. Its selective inhibition of the classical complement pathway aims to reduce the risk of infections from encapsulated bacteria by preserving the immune functions of the lectin and alternative pathways. Given the classical pathway's significant role in disease pathology, DNTH103 has the potential to be a best-in-class treatment for various autoimmune disorders with high unmet medical needs.

Dianthus Therapeutics is advancing its neuromuscular franchise with DNTH103, following the start of the Phase 2 MaGic trial for generalized Myasthenia Gravis in the first quarter of 2024, regulatory clearance for Multifocal Motor Neuropathy in the second quarter of 2024, and the planned initiation of a Phase 2 trial for Chronic Inflammatory Demyelinating Polyneuropathy in the second half of 2024.

Dianthus Therapeutics is a clinical-stage biotech company focused on creating and delivering innovative, best-in-class monoclonal antibodies with enhanced selectivity and potency. Located in New York City and Waltham, Mass., the company is led by a team of experienced biotech and pharma executives. They are committed to developing next-generation antibody complement therapeutics to provide transformative treatments for individuals suffering from severe autoimmune and inflammatory diseases.